About RxTA1: an independent Thymosin Alpha-1 research digest

What this site is

RxTA1 is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on Thymosin Alpha-1 (the thymic immune peptide, made as the synthetic drug thymalfasin). We read the studies, pull out what they actually measured, and write it up so a curious non-scientist can follow it — without losing the technical detail underneath. Every quantitative claim here is tied to a citation you can check on the references page.

We cover this compound the way an editorial desk covers a topic: organized, sourced, and honest about what's strong and what's shaky. That means we lead with the null phase-3 sepsis result as readily as the encouraging COVID-19 signals, because an honest digest reports both.

What this site is not

We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product — there is nothing to buy here, and you will not find a vendor link. Our work is editorial commentary on publicly available science.

The "rx" in our name is editorial framing — a position we occupy relative to the literature, signaling that we cover the clinical and regulatory side of this peptide — not a claim that this site prescribes, dispenses, or supplies anything. It does none of those things. There are no doctors here, no pharmacists, no clinical team, and no consultations.

How we handle accuracy

Thymosin Alpha-1 is one of the most-confused peptides out there, so we're deliberate about three things. First, we keep it distinct from the molecules it's mixed up with — thymosin beta-4 (TB-500), thymulin, thymopentin, thymalin, and its precursor prothymosin alpha — which we lay out on the mechanism of action page. Second, we treat it as the immune modulator it is, not as an anabolic or performance compound, because that's what the science says it is. Third, we report its US regulatory status plainly: it is not FDA-approved for marketing in the United States. We use only generic naming and we don't endorse any unapproved use.